Zobrazeno 1 - 10
of 164
pro vyhledávání: '"Anand N Malaviya"'
Autor:
Keerthi Talari, Vinod Ravindran, Pradip Kumar, Pravin Patil, Sarath Chandra Mouli, Syamasis Bandyopadhyay, Balebail G Dharmanand, Abhrajit Ray, Shankaralingam Rajeshwari, Sanjiv N Amin, Jyotsna Oak, Ved Chaturvedi, Anand N Malaviya, Sukumar Mukherjee
Publikováno v:
Indian Journal of Rheumatology, Vol 16, Iss 3, Pp 311-321 (2021)
Pharmacological management of rheumatoid arthritis (RA) includes synthetic and biological disease-modifying antirheumatic drugs (DMARDs). Biological DMARDs, also referred to as “biologics,” rapidly retard progression of the joint damage seen in R
Externí odkaz:
https://doaj.org/article/8afbed8558ee4037a7ddc3fa0f34c61f
Autor:
Anand N Malaviya
Publikováno v:
Indian Journal of Rheumatology, Vol 15, Iss 5, Pp 2-5 (2020)
Spondyloarthritis (SpA) is a family of systemic inflammatory rheumatic diseases that have been extensively reported and studied from India over the last >4 decades. The epidemiological studies estimate the prevalence of SpA to be 7–9 per 10,000 per
Externí odkaz:
https://doaj.org/article/5da9bc58cdb2492b8d1503d3befeb478
Autor:
Anand N Malaviya, Sanjiv Kapoor
Publikováno v:
Indian Journal of Rheumatology, Vol 13, Iss 3, Pp 186-194 (2018)
In a landmark breakthrough in 1976, Reichlin and Mattioli discovered the first myositis-specific antibody (MSA) called anti-Mi2 antibody that identified a specific clinical phenotype characterized by pathognomonic skin rash of dermatomyositis, typica
Externí odkaz:
https://doaj.org/article/4397fc74478141cbb74b7b3e2157638e
Autor:
Anand N Malaviya, Ravita Thakaran, Roopa Rawat, Sanjiv Kapoor, Shriram Garg, Sadhana S Baghel, Christy Messi, Vivekanand, Qamar Zaheer
Publikováno v:
Indian Journal of Rheumatology, Vol 13, Iss 4, Pp 233-239 (2018)
Objective: The objective of the study was to study the effectiveness of a recommended screening strategy for latent tuberculosis infection (LTBI) in patients with systemic inflammatory rheumatic diseases (SIRDs) treated with biological disease-modify
Externí odkaz:
https://doaj.org/article/4edd620fb0f14b138f61eb94f0873144
Autor:
Anand N Malaviya
Publikováno v:
Indian Journal of Rheumatology, Vol 16, Iss 2, Pp 240-241 (2021)
Externí odkaz:
https://doaj.org/article/4e03dc5918f943278c8a93d639223f03
Autor:
Anand N. Malaviya, Astha Sareen
Publikováno v:
Indian Journal of Rheumatology.
Autor:
Sarath Chandra Mouli, Keerthi Talari, Abhrajit Ray, Syamasis Bandyopadhyay, Balebail G. Dharmanand, Anand N. Malaviya, Shankaralingam Rajeshwari, Sanjiv Amin, Sukumar Mukherjee, Pradip Kumar, Pravin Patil, Vinod Ravindran, V K Chaturvedi, Jyotsna Oak
Publikováno v:
Indian Journal of Rheumatology, Vol 16, Iss 3, Pp 311-321 (2021)
Pharmacological management of rheumatoid arthritis (RA) includes synthetic and biological disease-modifying antirheumatic drugs (DMARDs). Biological DMARDs, also referred to as “biologics,” rapidly retard progression of the joint damage seen in R
Autor:
Anand N. Malaviya
Publikováno v:
Indian Journal of Rheumatology, Vol 15, Iss 6, Pp 209-216 (2020)
A careful literature search would reveal significant contributions by Indian clinicians and basic researchers in the field of Idiopathic inflammatory myopathies (IIMs). The main drug used for its treatment, methotrexate (MTX), was synthesized for the
Autor:
Anand N. Malaviya
Publikováno v:
Handbook of Biologics for Rheumatological Disorders ISBN: 9789811671999
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::25abc604dba2f923f195c012f3554322
https://doi.org/10.1007/978-981-16-7200-2_1
https://doi.org/10.1007/978-981-16-7200-2_1
Autor:
Anand N. Malaviya
Publikováno v:
International journal of rheumatic diseasesREFERENCES. 23(6)